<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20036">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01946711</url>
  </required_header>
  <id_info>
    <org_study_id>12082.101</org_study_id>
    <nct_id>NCT01946711</nct_id>
  </id_info>
  <brief_title>Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi</brief_title>
  <official_title>A Pilot Study to Investigate the Efficacy and Safety of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis (CRS) With Polyposis Nasi in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pari Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pari Pharma GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study should create data for the selection of a clinically relevant primary endpoint to
      assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the
      therapy of chronic rhinosinusitis (CRS) with polyposis nasi in adult patients. Ideally, the
      selected parameter should allow a correlation between an objective methodology and the
      clinical outcome of the study patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change of inflammation of the nasal mucosa and paranasal sinus</measure>
    <time_frame>Change from Baseline at Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Magnetic Resonance Imaging
Thickness of mucosa
Lund-Mackay-Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Treatment-emergent adverse events (AEs)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health-specific quality of life</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>SNOT 22 (Sino-Nasal Outcome Test 22)</description>
  </other_outcome>
  <other_outcome>
    <measure>Nasal obstruction</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rhinonanometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Expansion of polyposis nasi</measure>
    <time_frame>Week 0 and Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Endoscopy (classification according to Rasp et al. 2000)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rhinosinusitis</condition>
  <condition>Chronic Polyposis</condition>
  <arm_group>
    <arm_group_label>Buparid; Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buparid 1 mg budesonide/2 ml nebuliser solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budes; Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budes® Nasal Spray 50 µg budesonide/pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Inhalation</description>
    <arm_group_label>Buparid; Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Nasal spray</description>
    <arm_group_label>Budes; Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with confirmed diagnosis of chronic rhinosinusitis (CRS) with polyposis nasi
             grade I-II

          -  Patient with a PNIF of &gt; 7 l/min separated for left and right side of the nose

          -  Patient's written informed consent

          -  Male or female,&gt;= 18 years of age

          -  Patient is able to undergo nasal therapy without restrictions

          -  Capable of understanding the purpose and risk of the clinical trial

          -  Female patients with childbearing potential must have a negative urine pregnancy test
             prior to first IMP administration

          -  Patient has completed correctly the diary during the Wash-in Phase

        Exclusion Criteria:

          -  Patients with cystic fibrosis

          -  Patients with polyposis nasi grade III-IV

          -  Patients with prior sinonasal surgery (exemption: polypectomy)

          -  Patients with primary ciliaritis

          -  Patients with asthma

          -  Patients with active and symptomatic allergies against aeroallergens

          -  Pregnant or breastfeeding women

          -  Patients with suspected active upper airway infection

          -  Receipt of an investigational drug as part of a clinical trial within 4 weeks prior
             to first administration of IMP

          -  Drug or alcohol abuse

          -  End-stage malignancies

          -  Known hypersensitivity to Budesonide

          -  Patients with oral steroid therapy within the last 4 weeks

          -  Patients with frequent epistaxis (&gt; 2 per month)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Becker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Prante</last_name>
    <phone>+49 89 742846</phone>
    <phone_ext>830</phone_ext>
    <email>s.prante@pari.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerhard Boerner</last_name>
    <phone>+49 89 742846</phone>
    <phone_ext>59</phone_ext>
    <email>g.boerner@pari.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Canis, Prof</last_name>
      <phone>+49 551 3989</phone>
      <phone_ext>71</phone_ext>
      <email>martin.canis@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Canis, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University LMU Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Becker, MD</last_name>
      <phone>+49 89 7095</phone>
      <phone_ext>0</phone_ext>
      <email>sven.becker@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Sven Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRS</keyword>
  <keyword>polyposis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
